Source comparison
BPC-157 KPV Protocol Leaky Gut Research: Dosing Comparison
BPC-157 Tight junction stabilization via VEGF/FGF upregulation 250–500 mcg Subcutaneous Twice daily 4–8 weeks Essential for structural barrier repair. Oral bioavailability is lower but sufficient for localized gastric healing KPV NF-κB inhibition, blocks cytok
This comparison does not assign a generated winner or score.
- BPC-157
- Tight junction stabilization via VEGF/FGF upregulation
- 250–500 mcg
- Subcutaneous
- Twice daily
- 4–8 weeks
- Essential for structural barrier repair. Oral bioavailability is lower but sufficient for localized gastric healing
- KPV
- NF-κB inhibition, blocks cytokine transcription
- 500 mcg–1 mg
- Oral
- Once daily
- Most effective when taken on empty stomach. Mucosal contact is the goal, not systemic absorption
- Combined Protocol
- Dual mechanism: structural + anti-inflammatory
- BPC-157 250–500 mcg SC + KPV 500 mcg–1 mg oral
- Both routes
- BPC-157 twice daily, KPV once daily
- Outperforms monotherapy in published colitis models. Addresses barrier failure and inflammatory perpetuation simultaneously